Aficamten vs metoprolol for obstructive hypertrophic cardiomyopathy: MAPLE-HCM rationale, study design, and baseline characteristics
JACC. Heart failure (Online); 13 (2), 2025
Beta-blockers and nondihydropyridine calcium-channel blockers have been standard-of-care (SOC) medications for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), even though these agents do not directly affect the underlying pathophysiology of the disease. Cardiac myosin inhibitors...
Metoprolol/uso terapêutico, Cardiomiopatia Hipertrófica/tratamento farmacológico, Antagonistas de Receptores Adrenérgicos beta 1/uso terapêutico, Uracila/análogos & derivados, Resultado do Tratamento, Tolerância ao Exercício/efeitos dos fármacos, Obstrução da Via de Saída Ventricular Direita/tratamento farmacológico